Медицинский совет (Dec 2016)

Cardiovascular safety in the treatment of diabetes mellitus type 2: focus on alogliptin

  • A. L. Terekhova,
  • N. A. Petunina

DOI
https://doi.org/10.21518/2079-701X-2016-3-38-47
Journal volume & issue
Vol. 0, no. 3
pp. 38 – 47

Abstract

Read online

In the context of cardiac safety, the article discusses the prospects and benefits of a representatives of the DPP-4 inhibitors class - alogliptin (Vipidiya) for the management of hyperglycemia in patients with diabetes type 2 (T2DM).

Keywords